Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (221-230 of 284) with videos related to

Pageof 29
Sort By:
The Lancet. Oncology|May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.
British Journal of Cancer|November 28, 2024
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenonAndrea Pretta, Pina Ziranu, Eleonora Perissinotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2026
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatmentRoberto Moretto, Vittorio Studiale, Seung Won Hyun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerCarlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Clinical Colorectal Cancer|March 14, 2026
The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited DiseaseAndrea Pretta, Pina Ziranu, Francesca Bergamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONODaniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, Cosimo Rasola, Riccardo Lobefaro, et al.
Journal of the National Cancer Institute|September 1, 2021
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsRoberto Moretto, Andrew Elliott, Jian Zhang, et al.
Pageof 29

Showing results (221-230 of 284) with videos related to

Sort By:
Pageof 29
The Lancet. Oncology|May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2026
Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE StudyVeronica Conca, Daniele Rossini, Carlotta Antoniotti, et al.
British Journal of Cancer|November 28, 2024
Early onset metastatic colorectal cancer patients as a distinctive clinical and molecular phenomenonAndrea Pretta, Pina Ziranu, Eleonora Perissinotto, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2026
Circulating tumor DNA dynamics in patients with liver-limited metastatic colorectal cancer resected after first-line systemic treatmentRoberto Moretto, Vittorio Studiale, Seung Won Hyun, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2023
An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal CancerCarlotta Antoniotti, Alessandra Boccaccino, Robert Seitz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 12, 2024
Upfront Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Bevacizumab With or Without Atezolizumab for Patients With Metastatic Colorectal Cancer: Updated and Overall Survival Results of the ATEZOTRIBE StudyCarlotta Antoniotti, Daniele Rossini, Filippo Pietrantonio, et al.
Clinical Colorectal Cancer|March 14, 2026
The Impact of Surgical Resection in Early Onset Colorectal Cancer Patients With Liver Limited DiseaseAndrea Pretta, Pina Ziranu, Francesca Bergamo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONODaniele Rossini, Carlotta Antoniotti, Sara Lonardi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 3, 2023
Initial Panitumumab Plus Fluorouracil, Leucovorin, and Oxaliplatin or Plus Fluorouracil and Leucovorin in Elderly Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The PANDA Trial by the GONO FoundationSara Lonardi, Cosimo Rasola, Riccardo Lobefaro, et al.
Journal of the National Cancer Institute|September 1, 2021
Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic ImplicationsRoberto Moretto, Andrew Elliott, Jian Zhang, et al.
Pageof 29